Trinity Biotech plc (NASDAQ:TRIB) Short Interest Up 22.3% in October

by · The Cerbat Gem

Trinity Biotech plc (NASDAQ:TRIB – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 122,300 shares, a growth of 22.3% from the September 30th total of 100,000 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned approximately 4.72% of Trinity Biotech worth $390,000 at the end of the most recent reporting period. 78.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Trinity Biotech in a report on Friday, August 30th. They issued a “buy” rating on the stock.

Get Our Latest Analysis on TRIB

Trinity Biotech Stock Down 8.2 %

NASDAQ TRIB opened at $2.02 on Wednesday. The firm has a market cap of $15.39 million, a PE ratio of -0.75 and a beta of 1.20. Trinity Biotech has a 52 week low of $1.05 and a 52 week high of $3.55. The company has a 50 day moving average price of $1.67 and a 200 day moving average price of $2.04.

Trinity Biotech (NASDAQ:TRIB – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.10. The business had revenue of $15.84 million for the quarter, compared to analysts’ expectations of $15.75 million. On average, equities research analysts anticipate that Trinity Biotech will post -1.91 earnings per share for the current fiscal year.

About Trinity Biotech

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles